BIOGEN INC. Increase (Decrease) in Accounts Receivable
BIOGEN INC. (BIIB) reported Increase (Decrease) in Accounts Receivable of -$102.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-02-06
- BIOGEN INC. increase (decrease) in accounts receivable for the quarter ending 2023-03-31 was -$77.20M, a 188.23% decline year-over-year.
- BIOGEN INC. increase (decrease) in accounts receivable for the quarter ending 2022-12-31 was $93.90M.
- BIOGEN INC. increase (decrease) in accounts receivable for the quarter ending 2022-09-30 was $42.20M, a 21.42% decline year-over-year.
- BIOGEN INC. increase (decrease) in accounts receivable for the quarter ending 2022-06-30 was -$20.20M.
- BIOGEN INC. increase (decrease) in accounts receivable for fiscal 2025 was -$102.70M.
- BIOGEN INC. increase (decrease) in accounts receivable for fiscal 2024 was -$222.30M.
- BIOGEN INC. increase (decrease) in accounts receivable for fiscal 2023 was -$61.30M, a 130.14% decline from fiscal 2022.
- BIOGEN INC. increase (decrease) in accounts receivable for fiscal 2022 was $203.40M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 3 month as first filed | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 6 month as first filed | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 9 month as first filed | Increase (Decrease) in Accounts Receivable 12 month | Increase (Decrease) in Accounts Receivable 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | -$102.70M 10-K · filed 2026-02-06 | |||||||
| 2024-12-31 | -$222.30M 10-K · filed 2026-02-06 | |||||||
| 2023-12-31 | -$61.30M 10-K · filed 2026-02-06 | |||||||
| 2023-03-31 | -$77.20M 10-Q · filed 2023-04-25 | $16.70M derived: sum of 2 quarters · filed 2025-02-12 | $58.90M derived: sum of 3 quarters · filed 2025-02-12 | $38.70M derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2022-12-31 | $93.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $136.10M derived: sum of 2 quarters · filed 2025-02-12 | $115.90M derived: sum of 3 quarters · filed 2025-02-12 | $203.40M 10-K · filed 2025-02-12 | ||||
| 2022-09-30 | $42.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | $22.00M derived: sum of 2 quarters · filed 2022-10-25 | $109.50M 10-Q · filed 2022-10-25 | -$57.50M derived: sum of 4 quarters · filed 2024-02-14 | ||||
| 2022-06-30 | -$20.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-20 | $67.30M 10-Q · filed 2022-07-20 | -$99.70M derived: sum of 3 quarters · filed 2024-02-14 | -$46.00M derived: sum of 4 quarters · filed 2024-02-14 | ||||
| 2022-03-31 | $87.50M 10-Q · filed 2023-04-25 | -$79.50M derived: sum of 2 quarters · filed 2024-02-14 | -$25.80M derived: sum of 3 quarters · filed 2024-02-14 | -$200.10M derived: sum of 4 quarters · filed 2024-02-14 | ||||
| 2021-12-31 | -$167.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | -$113.30M derived: sum of 2 quarters · filed 2024-02-14 | -$287.60M derived: sum of 3 quarters · filed 2024-02-14 | -$324.80M 10-K · filed 2024-02-14 | ||||
| 2021-09-30 | $53.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | -$120.60M derived: sum of 2 quarters · filed 2022-10-25 | -$157.80M 10-Q · filed 2022-10-25 | -$296.30M derived: sum of 4 quarters · filed 2023-02-15 | ||||
| 2021-06-30 | -$174.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-20 | -$211.50M 10-Q · filed 2022-07-20 | -$350.00M derived: sum of 3 quarters · filed 2023-02-15 | -$483.10M derived: sum of 4 quarters · filed 2023-02-15 | ||||
| 2021-03-31 | -$37.20M 10-Q · filed 2022-05-03 | -$175.70M derived: sum of 2 quarters · filed 2023-02-15 | -$308.80M derived: sum of 3 quarters · filed 2023-02-15 | -$278.40M derived: sum of 4 quarters · filed 2023-02-15 | ||||
| 2020-12-31 | -$138.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | -$271.60M derived: sum of 2 quarters · filed 2023-02-15 | -$241.20M derived: sum of 3 quarters · filed 2023-02-15 | -$2.80M 10-K · filed 2023-02-15 | ||||
| 2020-09-30 | -$133.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-20 | -$102.70M derived: sum of 2 quarters · filed 2021-10-20 | $135.70M 10-Q · filed 2021-10-20 | $64.50M derived: sum of 4 quarters · filed 2022-02-03 | ||||
| 2020-06-30 | $30.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-22 | $268.80M 10-Q · filed 2021-07-22 | $197.60M derived: sum of 3 quarters · filed 2022-02-03 | $197.10M derived: sum of 4 quarters · filed 2022-02-03 | ||||
| 2020-03-31 | $238.40M 10-Q · filed 2021-04-22 | $167.20M derived: sum of 2 quarters · filed 2022-02-03 | $166.70M derived: sum of 3 quarters · filed 2022-02-03 | $33.00M derived: sum of 4 quarters · filed 2022-02-03 | ||||
| 2019-12-31 | -$71.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-03 | -$71.70M derived: sum of 2 quarters · filed 2022-02-03 | -$205.40M derived: sum of 3 quarters · filed 2022-02-03 | -$68.80M 10-K · filed 2022-02-03 | ||||
| 2019-09-30 | -$500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-21 | -$134.20M derived: sum of 2 quarters · filed 2020-10-21 | $2.40M 10-Q · filed 2020-10-21 | -$46.40M derived: sum of 4 quarters · filed 2021-02-03 | ||||
| 2019-06-30 | -$133.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-22 | $2.90M 10-Q · filed 2020-07-22 | -$45.90M derived: sum of 3 quarters · filed 2021-02-03 | $20.90M derived: sum of 4 quarters · filed 2021-02-03 | ||||
| 2019-03-31 | $136.60M 10-Q · filed 2020-04-23 | $87.80M derived: sum of 2 quarters · filed 2021-02-03 | $154.60M derived: sum of 3 quarters · filed 2021-02-03 | $207.80M derived: sum of 4 quarters · filed 2021-02-03 | ||||
| 2018-12-31 | -$48.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03 | $18.00M derived: sum of 2 quarters · filed 2021-02-03 | $71.20M derived: sum of 3 quarters · filed 2021-02-03 | $205.20M 10-K · filed 2021-02-03 | ||||
| 2018-09-30 | $66.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-22 | $120.00M derived: sum of 2 quarters · filed 2019-10-22 | $254.00M 10-Q · filed 2019-10-22 | $463.80M derived: sum of 4 quarters · filed 2020-02-06 | ||||
| 2018-06-30 | $53.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-24 | $187.20M 10-Q · filed 2019-07-24 | $397.00M derived: sum of 3 quarters · filed 2020-02-06 | $321.60M derived: sum of 4 quarters · filed 2020-02-06 | ||||
| 2018-03-31 | $134.00M 10-Q · filed 2019-04-24 | $343.80M derived: sum of 2 quarters · filed 2020-02-06 | $268.40M derived: sum of 3 quarters · filed 2020-02-06 | $373.90M derived: sum of 4 quarters · filed 2020-02-06 | ||||
| 2017-12-31 | $209.80M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-06 | $134.40M derived: sum of 2 quarters · filed 2020-02-06 | $239.90M derived: sum of 3 quarters · filed 2020-02-06 | $435.60M 10-K · filed 2020-02-06 | ||||
| 2017-09-30 | -$75.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-23 | $30.10M derived: sum of 2 quarters · filed 2018-10-23 | $225.80M 10-Q · filed 2018-10-23 | $229.10M derived: sum of 4 quarters · filed 2019-02-06 | ||||
| 2017-06-30 | $105.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-24 | $301.20M 10-Q · filed 2018-07-24 | $304.50M derived: sum of 3 quarters · filed 2019-02-06 | $477.60M derived: sum of 4 quarters · filed 2019-02-06 | ||||
| 2017-03-31 | $195.70M 10-Q · filed 2018-04-24 | $199.00M derived: sum of 2 quarters · filed 2019-02-06 | $372.10M derived: sum of 3 quarters · filed 2019-02-06 | $277.10M derived: sum of 4 quarters · filed 2019-02-06 | ||||
| 2016-12-31 | $3.30M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-06 | $176.40M derived: sum of 2 quarters · filed 2019-02-06 | $81.40M derived: sum of 3 quarters · filed 2019-02-06 | $241.40M 10-K · filed 2019-02-06 | ||||
| 2016-09-30 | $173.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-24 | $78.10M derived: sum of 2 quarters · filed 2017-10-24 | $238.10M 10-Q · filed 2017-10-24 | $145.50M derived: sum of 4 quarters · filed 2018-02-01 | ||||
| 2016-06-30 | -$95.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-25 | $65.00M 10-Q · filed 2017-07-25 | -$27.60M derived: sum of 3 quarters · filed 2018-02-01 | -$2.90M derived: sum of 4 quarters · filed 2018-02-01 | ||||
| 2016-03-31 | $160.00M 10-Q · filed 2017-04-25 | $67.40M derived: sum of 2 quarters · filed 2018-02-01 | $92.10M derived: sum of 3 quarters · filed 2018-02-01 | $2.70M derived: sum of 4 quarters · filed 2018-02-01 | ||||
| 2015-12-31 | -$92.60M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-01 | -$67.90M derived: sum of 2 quarters · filed 2018-02-01 | -$157.30M derived: sum of 3 quarters · filed 2018-02-01 | -$29.00M 10-K · filed 2018-02-01 | ||||
| 2015-09-30 | $24.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-26 | -$64.70M derived: sum of 2 quarters · filed 2016-10-26 | $63.60M 10-Q · filed 2016-10-26 | $63.61M 10-Q · filed 2015-10-21 | $278.94M derived: sum of 4 quarters · filed 2017-02-02 | |||
| 2015-06-30 | -$89.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-21 | $38.90M 10-Q · filed 2016-07-21 | $38.91M 10-Q · filed 2015-07-24 | $254.24M derived: sum of 3 quarters · filed 2017-02-02 | $362.34M derived: sum of 4 quarters · filed 2017-02-02 | |||
| 2015-03-31 | $128.30M 10-Q · filed 2016-04-21 | $128.29M 10-Q · filed 2015-04-24 | $343.64M derived: sum of 2 quarters · filed 2017-02-02 | $451.74M derived: sum of 3 quarters · filed 2017-02-02 | $443.01M derived: sum of 4 quarters · filed 2017-02-02 | |||
| 2014-12-31 | $215.34M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-02 | $323.44M derived: sum of 2 quarters · filed 2017-02-02 | $314.71M derived: sum of 3 quarters · filed 2017-02-02 | $512.40M 10-K · filed 2017-02-02 | $512.39M 10-K · filed 2015-02-04 | |||
| 2014-09-30 | $108.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-21 | $99.37M derived: sum of 2 quarters · filed 2015-10-21 | $297.06M 10-Q · filed 2015-10-21 | $203.90M derived: sum of 4 quarters · filed 2016-02-03 | ||||
| 2014-06-30 | -$8.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-24 | $188.96M 10-Q · filed 2015-07-24 | $95.80M derived: sum of 3 quarters · filed 2016-02-03 | $129.97M derived: sum of 4 quarters · filed 2016-02-03 | ||||
| 2014-03-31 | $197.69M 10-Q · filed 2015-04-24 | $104.53M derived: sum of 2 quarters · filed 2016-02-03 | $138.70M derived: sum of 3 quarters · filed 2016-02-03 | $248.84M derived: sum of 4 quarters · filed 2016-02-03 | ||||
| 2013-12-31 | -$93.16M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-03 | -$58.99M derived: sum of 2 quarters · filed 2016-02-03 | $51.15M derived: sum of 3 quarters · filed 2016-02-03 | $126.70M 10-K · filed 2016-02-03 | $126.75M 10-K · filed 2014-02-06 | |||
| 2013-09-30 | $34.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-22 | $144.31M derived: sum of 2 quarters · filed 2014-10-22 | $219.86M 10-Q · filed 2014-10-22 | $234.78M derived: sum of 4 quarters · filed 2015-02-04 | ||||
| 2013-06-30 | $110.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-23 | $185.69M 10-Q · filed 2014-07-23 | $200.60M derived: sum of 3 quarters · filed 2015-02-04 | $171.36M derived: sum of 4 quarters · filed 2015-02-04 | ||||
| 2013-03-31 | $75.55M 10-Q · filed 2014-04-23 | $90.46M derived: sum of 2 quarters · filed 2015-02-04 | $61.22M derived: sum of 3 quarters · filed 2015-02-04 | -$17.09M derived: sum of 4 quarters · filed 2015-02-04 | ||||
| 2012-12-31 | $14.91M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-04 | -$14.33M derived: sum of 2 quarters · filed 2015-02-04 | -$92.64M derived: sum of 3 quarters · filed 2015-02-04 | -$3.57M 10-K · filed 2015-02-04 | ||||
| 2012-09-30 | -$29.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-28 | -$107.55M derived: sum of 2 quarters · filed 2013-10-28 | -$18.49M 10-Q · filed 2013-10-28 | $37.55M derived: sum of 4 quarters · filed 2014-02-06 | ||||
| 2012-06-30 | -$78.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-25 | $10.76M 10-Q · filed 2013-07-25 | $66.80M derived: sum of 3 quarters · filed 2014-02-06 | $29.22M derived: sum of 4 quarters · filed 2014-02-06 | ||||
| 2012-03-31 | $89.07M 10-Q · filed 2013-04-25 | $145.11M derived: sum of 2 quarters · filed 2014-02-06 | $107.53M derived: sum of 3 quarters · filed 2014-02-06 | $71.73M derived: sum of 4 quarters · filed 2014-02-06 | ||||
| 2011-12-31 | $56.04M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-06 | $18.46M derived: sum of 2 quarters · filed 2014-02-06 | -$17.34M derived: sum of 3 quarters · filed 2014-02-06 | $73.37M 10-K · filed 2014-02-06 | ||||
| 2011-09-30 | -$37.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-25 | -$73.38M derived: sum of 2 quarters · filed 2012-10-25 | $17.33M 10-Q · filed 2012-10-25 | $43.84M derived: sum of 4 quarters · filed 2013-02-05 | ||||
| 2011-06-30 | -$35.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-24 | $54.91M 10-Q · filed 2012-07-24 | $81.42M derived: sum of 3 quarters · filed 2013-02-05 | $131.18M derived: sum of 4 quarters · filed 2013-02-05 | ||||
| 2011-03-31 | $90.71M 10-Q · filed 2012-05-01 | $117.22M derived: sum of 2 quarters · filed 2013-02-05 | $166.98M derived: sum of 3 quarters · filed 2013-02-05 | $169.74M derived: sum of 4 quarters · filed 2013-02-05 | ||||
| 2010-12-31 | $26.51M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $76.27M derived: sum of 2 quarters · filed 2013-02-05 | $79.03M derived: sum of 3 quarters · filed 2013-02-05 | $99.23M 10-K · filed 2013-02-05 | ||||
| 2010-09-30 | $49.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28 | $52.52M derived: sum of 2 quarters · filed 2011-10-28 | $72.72M 10-Q · filed 2011-10-28 | $76.95M derived: sum of 4 quarters · filed 2012-02-03 | ||||
| 2010-06-30 | $2.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-26 | $22.95M 10-Q · filed 2011-07-26 | $27.18M derived: sum of 3 quarters · filed 2012-02-03 | $59.55M derived: sum of 4 quarters · filed 2012-02-03 | ||||
| 2010-03-31 | $20.20M 10-Q · filed 2011-04-21 | -$20.20M 10-Q · filed 2010-04-20 | $24.43M derived: sum of 2 quarters · filed 2012-02-03 | $56.80M derived: sum of 3 quarters · filed 2012-02-03 | $158.58M derived: sum of 4 quarters · filed 2012-02-03 | |||
| 2009-12-31 | $4.23M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | $36.60M derived: sum of 2 quarters · filed 2012-02-03 | $138.38M derived: sum of 3 quarters · filed 2012-02-03 | $100.44M 10-K · filed 2012-02-03 | -$100.44M 10-K · filed 2010-02-09 | |||
| 2009-09-30 | $32.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-26 | $134.15M derived: sum of 2 quarters · filed 2010-10-26 | $96.22M 10-Q · filed 2010-10-26 | -$96.22M 10-Q · filed 2009-10-21 | $249.12M derived: sum of 4 quarters · filed 2011-02-04 | |||
| 2009-06-30 | $101.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-07-20 | $63.84M 10-Q · filed 2010-07-20 | -$63.84M 10-Q · filed 2009-07-17 | $216.74M derived: sum of 3 quarters · filed 2011-02-04 | $207.71M derived: sum of 4 quarters · filed 2011-02-04 | |||
| 2009-03-31 | -$37.94M 10-Q · filed 2010-04-20 | $114.97M derived: sum of 2 quarters · filed 2011-02-04 | $105.93M derived: sum of 3 quarters · filed 2011-02-04 | |||||
| 2008-12-31 | $152.90M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-04 | $143.87M derived: sum of 2 quarters · filed 2011-02-04 | $57.56M 10-K · filed 2011-02-04 | -$57.56M 10-K · filed 2010-02-09 | ||||
| 2008-09-30 | -$9.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-21 | -$95.34M 10-Q · filed 2009-10-21 | ||||||
| 2008-06-30 | -$86.30M 10-Q · filed 2009-07-17 | |||||||
| 2007-12-31 | -$70.70M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |